E. Mekov, M. Miravitlles, M. Topalovic, A. Singanayagam, Rosen Petkov
{"title":"Stepping Up the Personalized Approach in COPD with Machine Learning","authors":"E. Mekov, M. Miravitlles, M. Topalovic, A. Singanayagam, Rosen Petkov","doi":"10.2174/1573398x19666230607115316","DOIUrl":null,"url":null,"abstract":"\n\nThere is increasing interest in the application of artificial intelligence (AI) and machine learning (ML) in all fields of medicine to facilitate greater personalisation of management.\n\n\n\nML could be the next step of personalized medicine in chronic obstructive pulmonary disease (COPD) by giving the exact risk (risk for exacerbation, death, etc.) of every patient (based on his/her parameters like lung function, clinical data, demographics, previous exacerbations, etc.), thus providing a prognosis/risk for the specific patient based on individual characteristics (individual approach).\n\n\n\nML algorithm might utilise some traditional risk factors along with some others that may be location-specific (e.g. the risk of exacerbation thatmay be related to ambient pollution but that could vary massively between different countries, or between different regions of a particular country).\n\n\n\nThis is a step forward from the commonly used assignment of patients to a specific group for which prognosis/risk data are available (group approach).\n","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Respiratory Medicine Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573398x19666230607115316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
There is increasing interest in the application of artificial intelligence (AI) and machine learning (ML) in all fields of medicine to facilitate greater personalisation of management.
ML could be the next step of personalized medicine in chronic obstructive pulmonary disease (COPD) by giving the exact risk (risk for exacerbation, death, etc.) of every patient (based on his/her parameters like lung function, clinical data, demographics, previous exacerbations, etc.), thus providing a prognosis/risk for the specific patient based on individual characteristics (individual approach).
ML algorithm might utilise some traditional risk factors along with some others that may be location-specific (e.g. the risk of exacerbation thatmay be related to ambient pollution but that could vary massively between different countries, or between different regions of a particular country).
This is a step forward from the commonly used assignment of patients to a specific group for which prognosis/risk data are available (group approach).
期刊介绍:
Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.